Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials. [electronic resource]
Producer: 20200522Description: 375-387 p. digitalISSN:- 1179-1926
- Administration, Intravenous
- Adult
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Biological Availability
- Biological Variation, Population -- drug effects
- Body Weight -- drug effects
- Crohn Disease -- blood
- Female
- Humans
- Injections, Subcutaneous
- Interleukin-23 -- antagonists & inhibitors
- Male
- Middle Aged
- Models, Biological
- Psoriasis -- blood
- Serum Albumin -- drug effects
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.